Tirzepatide

Research Overview

Tirzepatide is a structurally distinct synthetic peptide that simultaneously co-activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) within a single unimolecular construct. This dual receptor targeting profile differentiates tirzepatide from single-agonist GLP-1R compounds and has positioned it as a significant tool compound in research examining the comparative roles of GIP and GLP-1 receptor pathways in insulin secretion signalling, energy homeostasis, and glycaemic regulation in preclinical models. The compound's unique structural architecture — a modified GIP analogue with a GLP-1R-active C-terminal sequence — offers researchers a platform for investigating incretin receptor crosstalk and co-agonism pharmacology. Supplied exclusively for laboratory and research use — not for human or animal consumption.

Tirzepatide was first described in the research literature as a "first-in-class dual GIP/GLP-1 receptor co-agonist," and its preclinical characterisation has been documented in studies examining incretin receptor signalling, pancreatic beta-cell response, hypothalamic energy regulation circuits, and adipose tissue metabolism in animal models. Both the GIPR and GLP-1R are expressed in the pancreas, central nervous system, and peripheral metabolic tissues, and co-agonism studies using tirzepatide have provided insight into whether simultaneous dual receptor activation produces additive or synergistic metabolic signalling effects compared to individual receptor agonism. Research interest in tirzepatide's receptor binding profile continues to inform broader investigations into incretin-based metabolic signalling biology. All outcomes referenced pertain to preclinical or investigational models and do not constitute evidence of clinical efficacy or safety in humans.